Recent Data on Bimekizumab for Hidradenitis Suppurativa

Survivors of SJS/TEN face severe long-term physical and psychological effects, with major gaps in post-discharge care, support, and physician guidance.

Immune-boosting herbs were linked to lower autoantibody rates in patients before dermatomyositis onset, suggesting activation of alternative immune pathways.

A study links seborrheic dermatitis to multiple epithelial barrier diseases, supporting broader assessment for inflammation and barrier dysfunction.

Delgocitinib has emerged as a promising treatment for CHE, addressing unmet needs and enhancing understanding of this complex condition, notes Raj Chovatiya, MD, PhD, MSCI.

Experts discussed safe and effective management strategies for patients with hidradenitis suppurativa at the 2025 Skin of Color Update.

Eliot F. Battle, MD, discusses how to effectively and successfully treat skin of color.